Prognostic Significance of Mixed-Lineage Leukemia (MLL) Gene Detected by Real-Time Fluorescence Quantitative PCR Assay in Acute Myeloid Leukemia

Background The overall prognosis of acute myeloid leukemia (AML) patients with mixed-lineage leukemia (MLL) gene-positivity is unfavorable. In this study, we evaluated the expression levels of the MLL gene in AML patients. Material/Methods We enrolled 68 MLL gene-positive patients out of 433 newly diagnosed AML patients, and 216 bone marrow samples were collected. Real-time fluorescence quantitative PCR (RQ-PCR) was used to precisely detect the expression levels of the MLL gene. Results We divided 41 patients into 2 groups according to the variation of MRD (minimal residual disease) level of the MLL gene. Group 1 (n=22) had a rapid reduction of MRD level to ≤10−4 in all samples collected in the first 3 chemotherapy cycles, while group 2 (n=19) had MRD levels constantly >10−4 in all samples collected in the first 3 chemotherapy cycles. Group 1 had a significantly better overall survival (p=0.001) and event-free survival (p=0.001) compared to group 2. Moreover, the patients with >10−4 MRD level before the start of HSCT (hematopoietic stem cell transplantation) had worse prognosis and higher risk of relapse compared to patients with ≤10−4 before the start of HSCT. Conclusions We found that a rapid reduction of MRD level to ≤10−4 appears to be a prerequisite for better overall survival and event-free survival during the treatment of AML. The MRD levels detected by RQ-PCR were basically in line with the clinical outcome and may be of great importance in guiding early allogeneic HSCT (allo-HSCT) treatment.

[1]  G. Avvisati,et al.  Pathogenetic, Clinical, and Prognostic Features of Adult t(4;11)(q21;q23)/MLL-AF4 Positive B-Cell Acute Lymphoblastic Leukemia , 2011, Advances in hematology.

[2]  F. Ravandi,et al.  Comparison of Multiparameter Flow Cytometry Immunophenotypic Analysis and Quantitative RT-PCR for the Detection of Minimal Residual Disease of Core Binding Factor Acute Myeloid Leukemia. , 2016, American journal of clinical pathology.

[3]  R. Foà,et al.  Clinical outcome and monitoring of minimal residual disease in patients with acute lymphoblastic leukemia expressing the MLL/ENL fusion gene , 2011, American journal of hematology.

[4]  Yang Wan,et al.  Prediction of outcomes by early treatment responses in childhood T-cell acute lymphoblastic leukemia: a retrospective study in China , 2015, BMC Pediatrics.

[5]  Xuan Zhou,et al.  Prognostic Significance of Monosomal Karyotype in Adult Patients With Acute Myeloid Leukemia Treated With Risk-Adapted Protocols. , 2015, Clinical lymphoma, myeloma & leukemia.

[6]  R. Hills,et al.  Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial. , 2015, The Lancet. Oncology.

[7]  C. Nakaseko,et al.  Efficacy of myeloablative allogeneic hematopoietic stem cell transplantation in adult patients with MLL-ELL-positive acute myeloid leukemia , 2015, International Journal of Hematology.

[8]  B. Hero,et al.  From initiation to eradication: the lifespan of an MLL-rearranged therapy-related paediatric AML , 2015, Bone Marrow Transplantation.

[9]  J. Esteve,et al.  Monosomal karyotype as an adverse prognostic factor in patients with acute myeloid leukemia treated with allogeneic hematopoietic stem-cell transplantation in first complete remission: a retrospective survey on behalf of the ALWP of the EBMT , 2016, Haematologica.

[10]  P. Szankasi,et al.  A novel approach to quantitating leukemia fusion transcripts by qRT-PCR without the need for standard curves. , 2015, Experimental and molecular pathology.

[11]  Marie S. Hasemann,et al.  Initiation of MLL-rearranged AML is dependent on C/EBPα , 2014, The Journal of experimental medicine.

[12]  H. Dombret,et al.  Prospective long-term minimal residual disease monitoring using RQ-PCR in RUNX1-RUNX1T1-positive acute myeloid leukemia: results of the French CBF-2006 trial , 2015, Haematologica.

[13]  S. Armstrong,et al.  Cell of origin determines clinically relevant subtypes of MLL-rearranged AML , 2013, Leukemia.

[14]  R. Orlowski,et al.  Chromosome 8q24.1/c-MYC abnormality: a marker for high-risk myeloma , 2015, Leukemia & lymphoma.

[15]  P. Pagel,et al.  The leukemogenic fusion gene MLL-AF9 alters microRNA expression pattern and inhibits monoblastic differentiation via miR-511 repression , 2016, Journal of experimental & clinical cancer research : CR.

[16]  T. Imamura,et al.  Sensitivity of MLL-rearranged AML cells to all-trans retinoic acid is associated with the level of H3K4me2 in the RARα promoter region , 2014, Blood Cancer Journal.

[17]  Li-li Wang,et al.  High Expression of c-kit mRNA Predicts Unfavorable Outcome in Adult Patients with t(8;21) Acute Myeloid Leukemia , 2015, PloS one.

[18]  N. Shen,et al.  AML1/ETO cooperates with HIF1α to promote leukemogenesis through DNMT3a transactivation , 2014, Leukemia.

[19]  B. Aronow,et al.  MEIS1 regulates an HLF-oxidative stress axis in MLL-fusion gene leukemia. , 2015, Blood.

[20]  M. Caligiuri,et al.  Epigenetic silencing of microRNA-193a contributes to leukemogenesis in t(8;21) acute myeloid leukemia by activating the PTEN/PI3K signal pathway. , 2013, Blood.

[21]  S. Bhatt,et al.  A rare cryptic and complex rearrangement leading to MLL-MLLT10 gene fusion masked by del(10)(p12) in a child with acute monoblastic leukemia (AML-M5). , 2012, Leukemia research : a Forum for Studies on Leukemia and Normal Hemopoiesis.

[22]  G. Basso,et al.  MLL-AF6 fusion oncogene sequesters AF6 into the nucleus to trigger RAS activation in myeloid leukemia. , 2014, Blood.

[23]  P. Woll,et al.  Clonal variegation and dynamic competition of leukemia-initiating cells in infant acute lymphoblastic leukemia with MLL rearrangement , 2014, Leukemia.

[24]  L. Michaux,et al.  A case with a cytogenetically cryptic variant of the inv(16)(p13q22)/t(16;16)(p13;q22). , 2014, Cancer genetics.

[25]  R. Hills,et al.  Minimal residual disease monitoring by quantitative RT-PCR in core binding factor AML allows risk stratification and predicts relapse: results of the United Kingdom MRC AML-15 trial. , 2007, Blood.

[26]  Sun-Hee Kim,et al.  Identification of Mixed Lineage Leukemia Gene (MLL)/MLLT10 Fusion Transcripts by Reverse Transcription-PCR and Sequencing in a Case of AML With a FISH-Negative Cryptic MLL Rearrangement , 2015, Annals of laboratory medicine.

[27]  S. Raimondi,et al.  Prognostic significance of additional cytogenetic aberrations in 733 de novo pediatric 11q23/MLL-rearranged AML patients: results of an international study. , 2011, Blood.

[28]  T. Haferlach,et al.  AML with gain of chromosome 8 as the sole chromosomal abnormality (+8sole) is associated with a specific molecular mutation pattern including ASXL1 mutations in 46.8% of the patients. , 2015, Leukemia research.

[29]  Kang Yu,et al.  MLL-ELL fusion gene in an acute myelomonocytic leukemia patient transformed from acute promyelocytic leukemia , 2015, Clinical case reports.

[30]  Y. Hayashi,et al.  Early use of allogeneic hematopoietic stem cell transplantation for infants with MLL gene-rearrangement-positive acute lymphoblastic leukemia , 2014, Leukemia.

[31]  M. Kyba,et al.  MLL-AF9 Expression in Hematopoietic Stem Cells Drives a Highly Invasive AML Expressing EMT-Related Genes Linked to Poor Outcome. , 2016, Cancer cell.